Therapeutic Sections > 6. Endocrine System ![]() |
It should be remembered that control of modifiable cardiovascular risk factors such as lipids and blood pressure are the most important interventions to be made in patients with type II diabetes.
National/local guidance
NICE guidance | NG28: Type 2 diabetes in adults - management, December 2015 TA248 Diabetes type 2 - exenatide prolonged release, February 2012. |
|
|
Prescribing notes
Exenatide, liraglutide and lixisenatide are incretin mimetics. They increase insulin secretion, suppresses glucagon secretion and slow gastric emptying. They are given by subcutaneous injection for treatment of type 2 diabetes.
Exenatide should be considered as part of a triple therapy regimen in carefully selected patients. It may be used in combination with metformin and a sulfonylurea in patients who have not achieved adequate control with these drugs in combination. It is used twice daily and may be given at any time within the 60 minutes period before the two main meals of the day, with doses at least 6 hours apart. It must not be given after meals. Exenatide is also licensed for use with basal insulin, co-prescribing with insulin is not covered in NICE guidance as this was not licensed at the time of publication.
Liraglutide/lixisenatide should be considered as part of a triple therapy regimen in carefully selected patients, also they may occasionally be used in dual therapy regimens if the person is intolerant of either metformin or a sulfonylurea, or treatment with metformin or a sulfonylurea is contraindicated and the person is intolerant of pioglitazone and gliptins, or treatment with pioglitazone and gliptins is contraindicated.
Exenatide prolonged release is a once weekly formulation and is used in carefully selected patients in triple therapy regimes.
Liraglutide should be considered for those patients unable to tolerate exenatide, who only have one main meal a day or with significant needle phobia. It is given once daily irrespective of meal times. Doses above 1.2mg daily should not be used.
Lixisenatide is licensed for use in both dual and triple therapy regimens. It can also be used together with basal insulin. It is not currently included in NICE guidance - it should be prescribed using the same criteria as per NICE guidance for exenatide and liraglutide. Please note: co-prescribing with insulin is not covered in NICE guidance as this was not licensed at the time of publication. It should not be combined with both basal insulin and a sulphonylurea due to increased risk of hypoglycaemia.
Treatment with an incretin mimetic should only be continued if a beneficial metabolic response has been shown (defined as a reduction of at leat 1 percentage point in HbA1c and a weight loss of at least 3% of initial body weight at 6 months).
![]() |
![]() |
![]() |
![]() |
1st Line | 2nd Line | Specialist Use | Hospital Only | Nice Guidance |
![]() | Hospital Choice | ![]() | Community Choice | ![]() | Specialist Initiation | ![]() | Shared Care Guidance |
1st Line | 2nd Line | Specialist Use | Hospital Only | Nice Guidance |
The server can not find the requested page:
There is no link available to the current electronic BNF website as this is undergoing a complete check due to some accuracy problems.
When using a NHS computer you can access the BNF and BNF for Children at https://www.medicinescomplete.com/mc/.
On this website you will now see four icons for these resources rather than two. Please use BNF Legacy or BNF for Children Legacy as these will take you to the original format of the online publications which do not have any errors or omissions.